2022
Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants
Bikdeli B, Tajrishi F, Sadeghipour P, Talasaz AH, Fanikos J, Lippi G, Siegal DM, Eikelboom JW, Monreal M, Jimenez D, Connors JM, Ageno W, Barnes GD, Piazza G, Angiolillo DJ, Parikh SA, Kirtane AJ, Lopes RD, Bhatt DL, Weitz JI, Mehran R, Krumholz HM, Goldhaber SZ, Lip GYH. Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. JAMA Cardiology 2022, 7: 747-759. PMID: 35648414, DOI: 10.1001/jamacardio.2022.1292.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsRandomized clinical trialsAcute VTE treatmentDose adjustmentOral anticoagulantsLow-intensity treatmentPrimary preventionLarge registriesVTE treatmentHigh-risk medical patientsStable atherosclerotic vascular diseaseHigh-risk cancer patientsLarge randomized clinical trialsSecondary VTE preventionPeripheral artery diseaseAtherosclerotic vascular diseaseDaily clinical practiceRoutine practice patternEvidence of safetyRecent revascularizationStroke preventionVTE preventionArtery diseaseMedical patientsCancer patients
2001
Cardiopatía isquémica en el anciano
Krumholz H. Cardiopatía isquémica en el anciano. Revista Española De Cardiología 2001, 54: 819-826. PMID: 11446955, DOI: 10.1016/s0300-8932(01)76405-6.Peer-Reviewed Original ResearchConceptsOlder patientsClinical trialsClinical practiceObservational studyPrognosis of illnessOlder patient groupGroup of patientsAcute myocardial infarctionDaily clinical practiceComorbidities increasesYounger patientsHeart failureMortal complicationsPatient groupMyocardial infarctionHigh incidencePatientsMedical focusFunctional changesField of cardiologyTrialsPublic healthDevelopment of strategiesHeterogeneous populationAge